Action of type III IFNs and their roles in immune responses;Działanie interferonów typu III i ich rola w odpowiedziach immunologicznych

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 64, Issue , 2010, Pages 522-533

  Domagalski, Krzysztof ^a,b   Tretyn, Andrzej ^b   Pawłowska, Małgorzata ^a   Szczepanek, Joanna ^a,b   Halota, Waldemar ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Antiviral activity; Immunomodulation; Interferon lambda; Virus infection

Indexed keywords

IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

HUMAN; IMMUNOLOGY; IMMUNOMODULATION; REVIEW; SIGNAL TRANSDUCTION; VIRUS ACTIVATION;

HUMANS; IMMUNOMODULATION; INTERLEUKINS; SIGNAL TRANSDUCTION; VIRUS ACTIVATION;

EID: 79952717943     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Almeida G. M., de Oliveira D. B., Magalhaes C. L., Bonjardim C. A., Ferreira P. C., Kroon E. G.: Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus. Antiviral Res., 2008;80:302-308
2. Ank N., Iversen M. B., Bartholdy C, Staeheli P., Hartmann R., Jensen U. B., Dagnaes-Hansen F., Thomsen A. R., Chen Z., Haugen H., Klucher K., Paludan S. R.: An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity. J. Immunol., 2008;180:2474-2485
3. Ank N., West H., Bartholdy C, Eriksson K., Thomsen A. R., Paludan S. R.: Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol., 2006;80:4501-4509
4. Ank N., West H., Paludan S. R.: IFN-λ: novel antiviral cytokines. J. Interferon Cytokine Res., 2006;26:373-379
5. Bandi P., Pagliaccetti N. E., Robek M. D.: Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J. Interferon Cytokine Res.; 30:123-134
6. Bartlett N. W., Buttigieg K., Kotenko S. V., Smith G. L.: Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol., 2005;86:1589-1596 (Pubitemid 40766871)
7. Bonjardim C. A., Ferreira P. C., Kroon E. G.: Interferons: signaling, antiviral and viral evasion. Immunol. Lett., 2009;122:1-11
8. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S. T., Otte J. M., Diebold J., Diepolder H., Adler B., Auernhammer C. J., Goke B., Dambacher J.: IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol., 2005;289:G960-G968 (Pubitemid 41532589)
9. Brand S., Zitzmann K., Dambacher J., Beigel F., Olszak T., Vlotides G., Eichhorst S. T., Goke B., Diepolder H., Auernhammer C. J.: SOCS-1 inhibits expression of the antiviral proteins 2', 5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem. Biophys. Res. Commun., 2005;331:543-548 (Pubitemid 40602671)
10. Caignard G., Bourai M., Jacob Y., Tangy F., Vidalain P. O.: Inhibition of IFN-α/β signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. Virology, 2009;383:112-120
11. Casrouge A., Zhang S. Y., Eidenschenk C, Jouanguy E., Puel A., Yang K., Alcais A., Picard C, Mahfoufi N., Nicolas N., Lorenzo L., Plancoulaine S., Senechal B., Geissmann F., Tabeta K., Hoebe K., Du X., Miller R. L., Heron B., Mignot C, de Villemeur T. B., Lebon P., Dulac O., Rozenberg F., Beutler B., Tardieu M., Abel L., Casanova J. L.: Herpes simplex virus encephalitis in human UNC-93B deficiency. Science, 2006;314:308-312 (Pubitemid 44571977)
12. Chi B., Dickensheets H. L., Spann K. M., Alston M. A., Luongo C, Dumoutier L., Huang J., Renauld J. C., Kotenko S. V, Roederer M., Beeler J. A., Donnelly R. P., Collins P. L., Rabin R. L.: Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J. Virol., 2006;80:5032-5040
13. Coccia E. M., Severa M., Giacomini E., Monneron D., Remoli M. E., Julkunen I., Cella M., Lande R., Uze G.: Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol., 2004;34:796-805 (Pubitemid 39255927)
14. Commins S., Steinke J. W., Borish L.: The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol., 2008;121:1108-1111
15. Contoli M., Message S. D., Laza-Stanca V, Edwards M. R., Wark PA., Bartlett N. W., Kebadze T., Mallia P., Stanciu LA., Parker H. L., Slater L., Lewis-Antes A., Kon O. M., Holgate S. T., Davies D. E., Kotenko S. V., Papi A., Johnston S. L.: Role of deficient type III interferon-lambda production in asthma exacerbations. Nat. Med., 2006;12:1023-1026 (Pubitemid 44353382)
16. Dai J., Megjugorac N. J., Gallagher G. E., Yu R. Y, Gallagher G.: IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood, 2009;113:5829-5838
17. Dellgren C, Gad H. H., Hamming O. J., Melchjorsen J., Hartmann R.: Human interferon-λ3 is a potent member of the type III interferon family. Antiviral activity of human interferon-λ3. Genes Immun., 2009;10:125-131
18. Donnelly R. P., Sheikh F., Kotenko S. V, Dickensheets H.: The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol., 2004;76:314-321 (Pubitemid 39006944)
19. Doyle S. E., Schreckhise H., Khuu-Duong K, Henderson K, Rosler R., Storey H., Yao L., Liu H., Barahmand-pour F., Sivakumar P., Chan C, Birks C, Foster D., Clegg C. H., Wietzke-Braun P., Mihm S., Klucher K. M.: Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology, 2006;44:896-906 (Pubitemid 46489554)
20. Dumoutier L., Tounsi A., Michiels T., Sommereyns C, Kotenko S. V, Renauld J. C.: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1: similarities with type I interferon signaling. J. Biol. Chem., 2004;279:32269-32274 (Pubitemid 39014676)
21. Farrar J. D., Asnagli H., Murphy K. M.: T helper subset development: roles of instruction, selection, and transcription. J. Clin. Invest., 2002;109:431-435 (Pubitemid 34171771)
22. Fensterl V, Sen G. C.: Interferons and viral infections. Biofactors, 2009;35:14-20
23. Fox B. A., Sheppard P. O., O'Hara P. J.: The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One, 2009;4:e4933
24. Gad H. H., Dellgren C, Hamming O. J., Vends S., Paludan S. R., Hartmann R.: Interferon-λ is functionally an interferon but structurally related to the interleukin-10 family. J. Biol. Chem., 2009;284:20869-20875
25. Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V, Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H., Muir A. J., Sulkowski M., McHutchison J. G., Goldstein D. B.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009;461:399-401
26. Holzinger D., Jorns C, Stertz S., Boisson-Dupuis S., Thimme R., Weidmann M., Casanova J. L., Haller O., Kochs G.: Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J. Virol., 2007;81:7776-7785 (Pubitemid 47047864)
27. Hong S. H., Cho O., Kim K., Shin H. J., Kotenko S. V, Park S.: Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res., 2007;126:245-249 (Pubitemid 46726717)
28. Hou W., Wang X., Ye L., Zhou L., Yang Z. Q., Riedel E., Ho W. Z.: Lambda interferon inhibits human immunodefciency virus type 1 infection of macrophages. J. Virol., 2009;83:3834-3842
29. Huang J., Smirnov S. V, Lewis-Antes A., Balan M., Li W., Tang S., Silke G. V, Putz M. M., Smith G. L., Kotenko S. V: Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc. Natl. Acad. Sci. USA, 2007;104:9822-9827 (Pubitemid 47175350)
30. Jordan W. J., Eskdale J., Boniotto M., Rodia M., Kellner D., Gallagher G.: Modulation of the human cytokine response by interferon lambda-1 (IFN-λ1/IL-29). Genes Immun., 2007;8:13-20 (Pubitemid 46164287)
31. Jordan W. J., Eskdale J., Srinivas S., Pekarek V., Kelner D., Rodia M., Gallagher G.: Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun., 2007;8:254-261 (Pubitemid 46679436)
32. Khaitov M. R., Laza-Stanca V., Edwards M. R., Walton R. P., Rohde G., Contoli M., Papi A., Stanciu L. A., Kotenko S. V., Johnston S. L.: Respiratory virus induction of alpha-, beta-and lambda-inter ferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy, 2009;64:375-386
33. Kopeć-Szlȩzak J.: Biology of dendritic cells. Onkol. Pol., 2008;11:106-110
34. Kotenko S. V., Gallagher G., Baurin V. V., Lewis-Antes A., Shen M., Shah N. K., Langer J. A., Sheikh F., Dickensheets H., Donnelly R. P.: IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol., 2003;4:69-77 (Pubitemid 36109115)
35. Kotenko S. V., Langer J. A.: Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol., 2004;4:593-608 (Pubitemid 38559077)
36. Langer J. A., Cutrone E. C., Kotenko S.: The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev., 2004;15:33-48 (Pubitemid 38121289)
37. Lasfar A., Lewis-Antes A., Smirnov S. V., Anantha S., Abushahba W., Tian B., Reuhl K., Dickensheets H., Sheikh F, Donnelly R. P., Raveche E., Kotenko S. V.: Characterization of the mouse IFN-lambda ligandreceptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res., 2006;66:4468-4477
38. Lazaro C. A., Chang M., Tang W., Campbell J., Sullivan D. G., Gretch D. R., Corey L., Coombs R. W., Fausto N.: Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am. J. Pathol., 2007;170:478-489 (Pubitemid 47339385)
39. Le Bon A., Tough D. F.: Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol., 2002;14:432-436 (Pubitemid 34671244)
40. Ma D., Jiang D., Qing M., Weidner J. M., Qu X., Guo H., Chang J., Gu B., Shi P. Y., Block T. M., Guo J. T.: Antiviral effect of interferon lambda against West Nile virus. Antiviral Res., 2009;83:53-60
41. Maher S. G., Romero-Weaver A. L., Scarzello A. J., Gamero A. M.: Interferon: cellular executioner or white knight? Curr. Med. Chem., 2007;14:1279-1289 (Pubitemid 46746361)
42. Maher S. G., Sheikh F., Scarzello A. J., Romero-Weaver A. L., Baker D. P., Donnelly R. P., Gamero A. M.: IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol. Ther., 2008;7:1109-1115
43. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E. S., Kotenko S. V., MacDonald M. R., Rice CM.: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology, 2006;131:1887-1898 (Pubitemid 44958521)
44. Meager A., Visvalingam K., Dilger P., Bryan D., Wadhwa M.: Biological activity of interleukins-28 and-29: comparison with type I interferons. Cytokine, 2005;31:109-118 (Pubitemid 40910226)
45. Megjugorac N. J., Gallagher G. E., Gallagher G.: Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J. Leukoc. Biol., 2009;86:1359-1363
46. Melchjorsen J., Siren J., Julkunen I., Paludan S. R., Matikainen S.: Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J. Gen. Virol., 2006;87:1099-1108
47. Mennechet F. J., Uze G.: Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood, 2006;107:4417-4423 (Pubitemid 43801368)
48. Miller D. M., Klucher K. M., Freeman J. A., Hausman D. F., Fontana D., Williams D. E.: Interferon lambda as a potential new therapeutic for hepatitis C. Ann. N. Y. Acad. Sci., 2009;1182:80-87
49. Mordstein M., Kochs G., Dumoutier L., Renauld J. C., Paludan S. R., Klucher K., Staeheli P.: Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog., 2008;4:e1000151
50. Morrow M. P, Pankhong P., Laddy D. J., Schoenly K. A., Yan J., Cisper N., Weiner D. B.: Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood, 2009;113:5868-5877
51. Nishimura G., Ikeda M., Mori K., Nakazawa T., Ariumi Y., Dansako H., Kato N.: Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents. Antiviral Res., 2009;82:42-50
52. Onoe K., Yanagawa Y., Minami K., Iijima N., Iwabuchi K.: Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol. Res., 2007;38:319-332 (Pubitemid 47574916)
53. Onoguchi K., Yoneyama M., Takemura A., Akira S., Taniguchi T., Namiki H., Fujita T.: Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem., 2007;282:7576-7581 (Pubitemid 47093699)
54. Osterlund P. I., Pietila T. E., Veckman V, Kotenko S. V., Julkunen I.: IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol., 2007;179:3434-3442
55. Pagliaccetti N. E., Eduardo R., Kleinstein S. H., Mu X. J., Bandi P., Robek M. D.: Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J. Biol. Chem., 2008;283:30079-30089
56. Pekarek V, Srinivas S., Eskdale J., Gallagher G.: Interferon lambda-1 (IFN-λ1/IL-29) induces ELR (-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-γ-independent manner. Induction of ELR-CXC chemokine mRNA by IFN-λ, 1. Genes Immun., 2007;8:177-180 (Pubitemid 46390918)
57. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J. F, Furrer H., Gunthard H. F, Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J. S., Berg T, Bergmann S., Negro F, Telenti A., Bochud PY: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology; 138:1338-1345
58. Robek M. D., Boyd B. S., Chisari F. V: Lambda interferon inhibits hepatitis B and C virus replication. J. Virol., 2005;79:3851-3854 (Pubitemid 40327973)
59. Rynda A., Maddaloni M., Ochoa-Reparaz J., Callis G., Pascual D. W.: IL-28 supplants requirement for T (reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE). PLoS One, 2010;5:e8720
60. Serra C, Biolchini A., Mei A., Kotenko S., Dolei A.: Type III and I interferons increase HIV uptake and replication in human cells that overexpress CD4, CCR5, and CXCR4. AIDS Res. Hum. Retroviruses, 2008;24:173-180 (Pubitemid 351282108)
61. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T. E., Kuestner R., Garrigues U., Birks C, Roraback J., Ostrander C, Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F. J., Tackett M., Krivan W., McKnight G., Clegg C, Foster D., Klucher K. M.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol., 2003;4:63-68 (Pubitemid 36104710)
62. Siren J., Pirhonen J., Julkunen I., Matikainen S.: IFN-α regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29. J Immunol, 2005;174:1932-1937 (Pubitemid 40223933)
63. Sommereyns C, Paul S., Staeheli P., Michiels T: IFN-lambda (IFN-λ,) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog., 2008;4:e1000017
64. Srinivas S., Dai J., Eskdale J., Gallagher G. E., Megjugorac N. J., Gallagher G.: Interferon-λ1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology, 2008;125:492-502
65. Stoltz M., Ahlm C, Lundkvist A., Klingstrom J.: Lambda interferon (IFN-λ) in serum is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to treatment with all IFNs and inhibits IFN-γ-induced nitric oxide production. J. Virol., 2007;81:8685-8691 (Pubitemid 47242842)
66. Suppiah V, Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M. L., Bassendine M., Spengler U., Dore G. J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V, Muller T., Bahlo M., Stewart G. J., Booth D. R., George J.: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet., 2009;41:1100-1104
67. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M.: Genome-wide association of IL28B with response to pegylated interferon-alp ha and ribavirin therapy for chronic hepatitis C. Nat. Genet., 2009;41:1105-1109
68. Thomas D. L., Thio C. L., Martin M. P., Qi Y., Ge D., O'Huigin C, Kidd J., Kidd K., Khakoo S. I., Alexander G., Goedert J. J., Kirk G. D., Donfeld S. M., Rosen H. R., Tobler L. H., Busch M. P., McHutchison J. G., Goldstein D. B., Carrington M.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009;461:798-801
69. Thomson S. J., Goh F. G., Banks H., Krausgruber T., Kotenko S. V., Foxwell B. M., Udalova I. A.: The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc. Natl. Acad. Sci. USA, 2009;106:11564-11569
70. Uze G., Monneron D.: IL-28 and IL-29: newcomers to the interferon family. Biochimie, 2007;89:729-734 (Pubitemid 47001631)
71. Wang J., Oberley-Deegan R., Wang S., Nikrad M., Funk C. J., Hartshorn K. L., Mason R. J.: Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-λ1) in response to influenza A infection. J. Immunol., 2009;182:1296-1304
72. Witte K., Gruetz G., Volk H. D., Looman A. C., Asadullah K., Sterry W., Sabat R., Wolk K.: Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun., 2009;10:702-714
73. Wolk K., Witte K., Witte E., Proesch S., Schulze-Tanzil G., Nasilowska K., Thilo J., Asadullah K., Sterry W., Volk H. D., Sabat R.: Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukoc. Biol., 2008;83:1181-1193 (Pubitemid 351960350)
74. Yang K., Puel A., Zhang S., Eidenschenk C, Ku C. L., Casrouge A., Picard C, von Bernuth H., Senechal B., Plancoulaine S., Al-Hajjar S., Al-Ghonaium A., Marodi L., Davidson D., Speert D., Roifman C, Garty B. Z., Ozinsky A., Barrat F. J., Coffman R. L., Miller R. L., Li X., Lebon P., Rodriguez-Gallego C, Chapel H., Geissmann F., Jouanguy E., Casanova J. L.: Human TLR-7-,-8-, and-9-mediated induction of IFN-alpha/beta and-lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity, 2005;23:465-478 (Pubitemid 41587887)
75. Zhang S. Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., Segal D., Sancho-Shimizu V., Lorenzo L., Puel A., Picard C, Chapgier A., Plancoulaine S., Titeux M., Cognet C, von Bernuth H., Ku C. L., Casrouge A., Zhang X. X., Barreiro L., Leonard J., Hamilton C, Lebon P., Heron B., Vallee L., Quintana-Murci L., Hovnanian A., Rozenberg F, Vivier E., Geissmann F, Tardieu M., Abel L., Casanova J. L.: TLR3 defciency in patients with herpes simplex encephalitis. Science, 2007;317:1522-1527 (Pubitemid 47417427)
76. Zhou L., Wang X., Wang Y. J., Zhou Y., Hu S., Ye L., Hou W., Li H., Ho W. Z.: Activation of toll-like receptor-3 induces interferon-λ, expression in human neuronal cells. Neuroscience, 2009;159:629-637
77. Zhou Z., Hamming O. J., Ank N., Paludan S. R., Nielsen A. L., Hartmann R.: Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol., 2007;81:7749-7758 (Pubitemid 47047861)
78. Żeromski J., Samara H., Mozer-Lisewska I.: Komórki dendrytyczne: czy wszystko o nich wiemy? Postepy Biol. Kom., 2007;34:541-556